Abstract:Objective: To investigate the DNMT3A R882 mutation in children with acute myeloid leukemia (AML) and its effect on prognosis. Methods: A total of 148 children with AML treated in our hospital (March 2017 and March 2020) were selected for this study. According to the detection results of DNMT3A R882 mutations, the children were assigned into the mutation group (n = 20) and the non-mutation group (n = 128). The correlation of DNMT3A R882 mutation and non-mutation with other gene mutations in the children was observed; the clinical characteristics and cellular immune phenotype, as well as clinical remission rate, recurrence rate (RR) and overall survival (OS) after treatment were compared. Results: By genetic mutation detection, there were 20 cases (13.51%) with DNMT3A R882 mutation and 128 cases (86.49%) without DNMT3A R882 mutation among the children with 148 AML; the DNMT3A and NPM1 mutations were similar in the two groups (P > 0.05). The difference in the CEBPA mutation, FLT3-ITD mutation, and double mutation of FLT3-ITD and CEBPA was statistically significant between the two groups (P < 0.05). The white blood cell count, hemoglobin, and platelet levels in the DNMT3A R882 mutant group were higher than those in the non-mutation group (P < 0.05). The positive detection rates of CD15 (80.00%) and CD33 (75.00%) were increased in the DNMT3A R882 mutation group compared with the non-mutation group (35.16% vs 36.72%), whereas the detection rate of CD34 (7.50%) was reduced (P < 0.05). After treatment, the RR (90%) was significantly higher in the DNMT3A R882 mutation group than in the non-mutation group (13.28%), but the OS and disease-free survival (DFS) in the DNMT3A R882 mutation group were shorter than those in the non-mutation group (P < 0.05). The survival time in the DNMT3A R882 mutation group was shorter than that in the non-mutation group (chi(2) = 2.720, P = 0.032). WBC, PLT, HIB, CD15, CD34, and CD33 were independent risk factors for AML in the mutation group. Conclusion: DNMT3A R882 mutation is a common expression method of DNMT3A in AML. Children with DNMT3A R882 mutations have a higher white blood cell count, hemoglobin, and platelet levels. The cellular immune phenotypes CD15, CD33 are highly expressed, CD34 is lowly expressed, and DNMT3A R882 mutation may be associated with a poor prognosis in AML patients.

DNMT3A-R882: a mutation with many paradoxes

DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

DNMT3A R882 mutation in children with acute myeloid leukemia and its role in prognosis

Dnmt3a Arg882 Mutation Drives Chronic Myelomonocytic Leukemia Through Disturbing Gene Expression/Dna Methylation in Hematopoietic Cells

Effect of DNMT3A R882H Hot Spot Mutations on DDX43 Promoter Methylation in Acute Myeloid Leukemia

Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations

DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming

Novel Impact Of The Dnmt3a R882h Mutation On Gsh Metabolism In A K562 Cell Model Established By Talens

Significance of targeting DNMT3A mutations in AML

[Analysis of DNMT3a gene mutations in acute myelogenous leukemia]

Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia

Germline DNMT3A mutation in familial acute myeloid leukaemia

3141 – LEUKEMIA-ASSOCIATED MUTATIONS IN DNMT3A MEDIATE SENSITIVITY TO REPLICATION STRESS INDUCED BY NUCLEOSIDE ANALOGS

Biologico-clinical significance of DNMT3A variants expression in acute myeloid leukemia.

Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML

Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients

Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients

The impact of DNMT3A variant allele frequency and two different comutations on patients with de novo cytogenetically normal acute myeloid leukemia

Landscape of biallelic DNMT3A mutant myeloid neoplasms

Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation